Level C· Early human research exploring benefitsCohort StudyEurope PMCOpen access

Intradiscal platelet-rich plasma for discogenic low back pain: a prospective cohort study of early clinical outcomes and quantitative MRI findings

Pan X., Peng G., Yao Q., Liu Z., Zhang X., Jiang W.

Cohort Study on Back Pain, Disc Degeneration, published in Sci Rep (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Cohort Study
Journal
Sci Rep (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41876737
PMCID
PMC13139604
DOI
10.1038/s41598-026-42909-x

Abstract (original English)

Discogenic low back pain (DLBP) is a major cause of disability. Platelet-rich plasma (PRP) has shown regenerative potential in preclinical models, but clinical results remain heterogeneous and early biological responses in humans are incompletely understood. We conducted a prospective cohort study (November 2023-October 2024) to evaluate early clinical outcomes and quantitative MRI (qMRI) changes after intradiscal PRP injection for DLBP. Symptom scores (VAS, ODI and FRI) and qMRI measures (whole-disc T2 and vertebral marrow fat fraction in adjacent vertebrae) were assessed at baseline and at 1, 3 and 6 months. A composite minimal clinically important difference (MCID) was predefined as a ≥ 30% reduction from baseline in both VAS and ODI. Longitudinal changes were analyzed using linear mixed-effects models, and baseline-to-6-month changes were correlated using Pearson tests. Forty-five patients were recruited and 29 completed follow-up. VAS, ODI and FRI decreased significantly over time (all P < 0.001), and 79.3% achieved the composite MCID at 6 months. Vertebral marrow fat fraction adjacent to the treated disc declined significantly (P < 0.001) and correlated with improvements in VAS, ODI and FRI (r ≈ 0.46-0.56; P < 0.01), whereas changes in whole-disc T2 were small and not associated with symptom change. No treatment-related complications were observed. Intradiscal PRP appeare

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansLow Back PainMagnetic Resonance ImagingTreatment OutcomeProspective StudiesAdultMiddle AgedFemaleMalePlatelet-Rich Plasma

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research